(190) Development of polymer-lipid hybrid Hepa-SENS platform technology for the treatment of liver disease
Introduction: Lipid nanoparticles are widely recognized as efficient and relatively safe delivery vehicles for mRNA. However, most systemically administered LNP–mRNA formulations tend to accumulate in the liver, which may lead to hepatotoxicity due to lipid overload. Furthermore, repeated dosing often triggers the generation of anti-drug antibodies, including neutralizing antibodies, posing challenges in therapeutic applications that require long-term or repeated administration. In this study, we present a novel delivery system specifically designed to address these challenges.
Learning Objectives:
To explain the mechanism of the Hepa-SENS platform delivery to hepatocytes.
To evaluate the in vivo efficacy and safety profile of Hepa-SENS™.
